XBIT (XBiotech) Other Current Receivables: $0.30 Mil (As of Mar. 2026)


XBIT XBiotech Inc XBIT
30 GF Score
Price $2.30
! 2 Warning Signs
View Full Analysis

What is XBiotech Other Current Receivables?

XBiotech XBIT 30 Other Current Receivables is $0.30 Mil as of Mar. 2026. GuruFocus rates XBIT with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

XBiotech's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.30 Mil.

XBiotech's quarterly Other Current Receivables declined from Sep. 2025 ($0.53 Mil) to Dec. 2025 ($0.36 Mil) but then stayed the same from Dec. 2025 ($0.36 Mil) to Mar. 2026 ($0.30 Mil).

XBiotech's annual Other Current Receivables declined from Dec. 2023 ($0.94 Mil) to Dec. 2024 ($0.86 Mil) and declined from Dec. 2024 ($0.86 Mil) to Dec. 2025 ($0.36 Mil).

XBiotech Other Current Receivables Related Terms

XBiotech Other Current Receivables Historical Data

* Premium members only.

The historical data trend for XBiotech's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XBiotech Other Current Receivables Chart

XBiotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.95 1.76 0.94 0.86 0.36

XBiotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.64 0.53 0.36 0.30
XBIT
30GF Score
XBiotech Inc XBIT
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XBiotech Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.30 Mil mean?
XBiotech (XBIT) has a Other Current Receivables of $0.30 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on XBiotech and its competitors.
Is XBiotech's Other Current Receivables too high?
XBiotech's current Other Current Receivables is $0.30 Mil. Overall, XBiotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does XBiotech's Other Current Receivables compare to ACRV and EXOZ?
XBiotech's Other Current Receivables of $0.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on XBiotech and its competitors. XBiotech's current Other Current Receivables is $0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XBiotech stock overvalued right now?
XBiotech (XBIT) has a current Other Current Receivables of $0.30 Mil. The current Other Current Receivables is $0.30 Mil. XBiotech's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For XBiotech (XBIT), the current Other Current Receivables is $0.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XBiotech Business Description

Other Exchanges 4XB:Germany
Address 5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
30GF Score

Get the complete analysis for XBIT

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.30
Price